Automate Your Wheel Strategy on ALVO
With Tiblio's Option Bot, you can configure your own wheel strategy including ALVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ALVO
- Rev/Share 1.9916
- Book/Share -0.6163
- PB -7.5286
- Debt/Equity -7.3157
- CurrentRatio 1.8211
- ROIC 0.0883
- MktCap 1445829355.0
- FreeCF/Share -0.4972
- PFCF -10.3404
- PE 20.5958
- Debt/Assets 0.9104
- DivYield 0
- ROE -0.2057
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ALVO | Deutsche Bank | Buy | Hold | -- | $8 | Nov. 4, 2025 |
| Upgrade | ALVO | Morgan Stanley | Equal Weight | Overweight | -- | $14 | Oct. 14, 2025 |
| Upgrade | ALVO | Deutsche Bank | Hold | Buy | -- | $14 | Sept. 23, 2025 |
| Initiation | ALVO | UBS | -- | Buy | -- | $18 | Feb. 14, 2025 |
News
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
Published: February 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ALVO) today announced the availability of SELARSDI™ (ustekinumab-aekn) injection in the U.S., a biosimilar to Stelara® (ustekinumab), for the treatment of psoriatic arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, pediatric plaque psoriasis and pediatric psoriatic arthritis. This is the second biosimilar now available in the U.S. market under the Teva and Alvotech strategic partnership. The FDA has provisionally determined that SELARSDI will be interchangeable with the reference biologic Stelara®, following the expiration of exclusivity for the first interchangeable biosimilar, on April 30, 2025.
Read More
FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea
Published: February 18, 2025 by: Investopedia
Sentiment: Neutral
Teva Pharmaceutical Industries (TEVA) and partner Alvotech (ALVO) said the Food and Drug Administration (FDA) agreed to review their AVTO6 treatment for eye disorders.
Read More
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept), a biologic used to treat eye disorders, including diseases which can lead to vision loss or blindness. The process to obtain regulatory approval is anticipated to be completed in the fourth quarter of 2025.
Read More
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept), a biologic used to treat eye disorders, including diseases which can lead to vision loss or blindness. The process to obtain regulatory approval is anticipated to be completed …
Read More
About Alvotech (ALVO)
- IPO Date 2022-06-16
- Website https://www.alvotech.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Vilhelm Robert Wessman
- Employees 1012